Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.
暂无分享,去创建一个
P. Neven | Chiun-Sheng Huang | H. Rugo | M. Goetz | N. Harbeck | C. Shimizu | M. Campone | S. Johnston | J. Huober | J. O’Shaughnessy | E. Senkus | Miguel Martín | M. Toi | S. Tolaney | L. Del Mastro | B. San Antonio | I. Çiçin | A. Shahir | V. André | L. Testa | P. Rastogi | G. G. Jaliffe | R. Wei | M. Muñoz | M. Munoz